Literature DB >> 6306333

Converting enzyme activity and essential hypertension.

A Overlack, M Higuchi, R Kolloch, K O Stumpe.   

Abstract

Serum ACE-activity was studied in 27 young patients with uncomplicated essential hypertension. The possible importance of an increase in ACE for the pathogenesis of essential hypertension was evaluated by comparing the ACE levels to PRA, the plasma concentrations of angiotensin II and to the blood pressure lowering effect of captopril. Mean ACE-activity was slightly but significantly elevated in the hypertensive patients when compared to 28 normotensive control subjects. ACE-activity was not correlated to PRA, angiotensin II or the decrease in blood pressure following captopril. It is concluded that the increase in ACE-activity in essential hypertension is not of pathophysiological or clinical significance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306333     DOI: 10.1007/bf01485031

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Elevation of serum angiotensin-converting enzyme in Gaucher's disease.

Authors:  J Lieberman; E Beutler
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

2.  The angiotensin I converting enzyme.

Authors:  E G Erdös
Journal:  Fed Proc       Date:  1977-04

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Plasma bradykinin levels and urinary kallikrein excretion in normal renin essential hypertension.

Authors:  J H Mersey; G H Williams; R Emanuel; R G Dluhy; P Y Wong; T J Moore
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

5.  Serum angiotensin-converting enzyme: elevations in diabetes mellitus.

Authors:  J Lieberman; A Sastre
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

6.  Angiotensin II in essential hypertension.

Authors:  D G Beevers; J J Morton; C S Nelson; P L Padfield; M Titterington; M Tree
Journal:  Br Med J       Date:  1977-02-12

7.  Elevated angiotensin-I-converting enzyme (ACE) in patients with essential hypertension.

Authors:  H Schweisfurth; A Kment; H Dahlheim; B E Strauer
Journal:  Klin Wochenschr       Date:  1982-01-04

8.  Increased levels of serum angiotensin-converting enzyme activity in hyperthyroidism.

Authors:  H Yotsumoto; Y Imai; N Kuzuya; H Uchimura; F Matsuzaki
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391

Review 9.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

10.  Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders.

Authors:  P Studdy; R Bird; D G James
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

View more
  3 in total

1.  Influences of the chemical structure on the activity of new inhibitory compounds of the angiotensin-converting enzyme.

Authors:  W E Siems; G Heder; K D Jentzsch; U Burkhardt; S Johne; H Kühmstedt; K Kottke; I Wunderlich; P Oehme
Journal:  Experientia       Date:  1986-02-15

2.  Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease.

Authors:  G Schernthaner; C Schwarzer; R Kuzmits; M M Müller; U Klemen; H Freyler
Journal:  J Clin Pathol       Date:  1984-03       Impact factor: 3.411

3.  Associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population.

Authors:  Qingfang He; Chunhong Fan; Min Yu; Gina Wallar; Zuo-Feng Zhang; Lixin Wang; Xinwei Zhang; Ruying Hu
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.